Navigation Links
Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014
Date:12/14/2009

WALTHAM, Mass., Dec. 14 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, increased use of safety devices for small-bore connectors for disposable enteral feeding devices will be a key driver of the enteral feeding device markets in both the US and Europe. MRG's new US and European Markets for Enteral Feeding Devices 2010 report finds that the giving set segment will experience the greatest impact from facilities switching to safety devices because more than 150 million of these units are sold annually in these two regions.

The European Committee for Standardization, the US Food and Drug Administration, the Association for the Advancement of Medical Instrumentation, and the International Organization for Standardization (ISO) are all working on a series of standards for small-bore connectors so that intravenous (IV), urethral/urinary, dialysis and other tubing systems cannot accidentally be connected to each other. Luer-type connectors are currently common on many different types of medical tubing, providing the potential for enteral tubing to be accidentally connected to tubing designed to give access to parts of the body other than the digestive tract. Such improper connections can result in enteral feed being delivered into the lungs or veins, causing severe injury or even patient death.

"The new small-bore connector safety standards are expected to be released in early 2010. Safety devices will reach the market in late 2010 and will have fully penetrated the market by 2013," says Sara Scharf, Analyst at MRG. "In the meantime, companies such as Nestle Nutrition and Abbott Nutrition have already developed special proprietary connectors that make their brands of enteral tubing incompatible with the connectors on IV lines. Safety products cost more than standard products so their increased adoption will raise prices in all segments of
'/>"/>

SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
2. Negative Pressure Wound Devices Draw FDA Notice, Advice
3. Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide
4. Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective
5. Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets
6. Worlds Only FDA Approved Home Needle Destruction Device is in Production
7. Cardio Vascular Medical Device Announces Forward Stock Split
8. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
9. Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015
10. Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014)
11. Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has ... the company’s chief executive officer has announced a new promotion ... offered at discounted prices, from 15 to 26 percent off. ... in huge demand in the current market. We are excited ... a lot of high quality products for sale. Many of ...
(Date:7/13/2014)... 13, 2014 Micro irrigation systems are ... water dispersal as wells as to maintain soil quality. ... projected to become a dominant revenue generator for manufacturers ... to reduce resource costs has led to the adoption ... and has further caused massive demand for micro irrigation ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... 2014 A Massachusetts couple who have ... risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... federal regulators, as they presented poignant testimony on the ... Administration (FDA) advisory panel meeting convened to address the ... Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and his ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
Breaking Medicine News(10 mins):Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Asia are born and die without leaving a trace ... information on which to base public health decisions, a ... colleagues say in a paper published today (Oct. 29, ... However, affordable solutions exist to collect these vital statistics ...
... Treatment Times, Optimize Planning, Objectives and Offer Increased ... Oct. 29 Accuray,Incorporated (Nasdaq: ARAY ), ... today four new products designed to improve treatment ... in radiation delivery. These products are being launched ...
... Ongoing Oncology Program for MDX-1106, PRINCETON, N.J., ... Inc. (Nasdaq: MEDX ) announced today the ... with the U.S. Food &,Drug Administration (FDA) for ... a fully human anti-PD-1 antibody being,investigated for the ...
... SAN DIEGO, Oct. 29 Arena Pharmaceuticals,Inc. (Nasdaq: ... to,present at the BIOCOM Investor Conference on November 2, ... at the Marriott Del Mar Hotel in San,Diego, California. ... to provide a corporate overview of the company and,its ...
... Office of Technology and Intellectual Property, has received a ... Society of U.S.A. and Canada. , The award stems ... University of Chicago and the Mayo Clinic. The deal ... risk of side effects from a standard first-line treatment ...
... S.C., Oct. 29 The federal government has,approved ... Medicare,Advantage and Medicare Part D product offerings. Enrollment ... BlueCross, products include two PPO plans, Medicare Blue(SM) ... Blue(SM),Private; and two prescription drug plans, MedBlue(SM) Rx ...
Cached Medicine News:Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 2Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 3Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 4Health News:Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting 5Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 2Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 3Health News:Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody 4Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 2Health News:Arena Pharmaceuticals to Present at the BIOCOM Investor Conference 3Health News:Gene screen patent leads to 'Deal of Distinction' 2
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: